After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor anti...
Reminder - On Wednesday June 6, 2018 at 10:00AM PST, we will be hosting a webinar regarding the chan...
On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...
CTS communications distributed on July 6th and July 20th.In working with Grifols on the availability...
On September 23, 2019, the new CTS Laboratory Information System successfully implemented in Da...
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...